Citations

Clear

4847 citation(s) found for "Yu, Eric".

Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316)
Deutsch, Gary B. , Deneve, Jeremiah L. , Al-Kasspooles, Mazin F, Nfonsam, Valentine , Gunderson, Camille C., Secord, Angeles Alvarez , Rodgers, Phillip , Hendren, Samantha , Silberfein, Eric J. , Grant, Marcia , Sloan, Jeff A. , Arnold, Kathryn B. , Sloan, Jeff, Sun, Virginia Chih-Yi , Anderson, Garnet L. , Krouse, Robert S.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | May 24, 2019 | Volume: 37 | Issue: 1 | Pages: 12-18

10.1177/1049909119851471 | PMID 31122027 Get It

Background: Prospective, randomized trials are needed to determine optimal treatment approaches for palliative care problems such as malignant bowel obstruction (MBO). Randomization poses unique issues for such studies, especially with divergent treatment approaches and varying levels of equipoise. We report our experience accruing randomized patients to the Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction (SWOG S1316) study, comparing surgical and nonsurgical management of MBO. Methods: Patients with MBO who were surgical candidates and had treatment equipoise were accrued and offered randomization to surgical or nonsurgical management. Patients choosing nonrandomization were offered prospective observation. Trial details are listed on www.clinicaltrials.gov (NCT #02270450). An accrual algorithm was developed to enhance enrollment. Results: Accrual is ongoing with 176 patients enrolled. Most (89%) patients chose nonrandomization, opting for nonsurgical management. Of 25 sites that have accrued to this study, 6 enrolled patients on the randomization arm. Approximately 59% (20/34) of the randomization accrual goal has been achieved. Patient-related factors and clinician bias have been the most prevalent reasons for lack of randomization. An algorithm was developed from clinician experience to aid randomization. Using principles in this tool, repeated physician conversations discussing treatment options and goals of care, and a supportive team–approach has helped increase accrual. Conclusions: Experience gained from the S1316 study can aid future palliative care trials. Although difficult, it is possible to randomize patients to palliative studies by giving clinicians clear recommendations utilizing an algorithm of conversation, allotment of necessary time to discuss the trial, and encouragement to overcome internal bias.
Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer
Fischer‐Valuck, Benjamin W. , Michalski, Jeff M. , Christodouleas, John P. , DeWees, T.A. , Kim, Eric H. , Smith, Zachary L. , Andriole, Gerald L. , Arora, Vivek , Bullock, Arnold, Carmona, Ruben, Figenshau, Robert S., Grubb, Robert L. , Guzzo, Thomas J., Knoche, E, Malkowicz, S. Bruce, Mamtani, Ronac , Pachynski, Russell K. , Roth, Bruce J. , Zaghloul, Mohamed S. , Baumann, Brian C. , DeWees, Todd A, Mamtani, Ronac , Baumann, Brian C , DeWees, Todd A , Pachynski, Russell K , Mitra, Nandita , Knoche, Eric M., Gay, Hiram A.

Mayo Clinic

Cancer Medicine | May 23, 2019 | Volume: 8 | Issue: 8 | Pages: 3698-3709

10.1002/cam4.2102 | PMID 31119885 Get It

AbstractBackgroundLocal‐regional failure (LF) for locally advanced bladder cancer (LABC) after radical cystectomy (RC) is common even with chemotherapy and is associated with high morbidity/mortality. Postoperative radiotherapy (PORT) can reduce LF and may enhance overall survival (OS) but has no defined role. We hypothesized that the addition of PORT would improve OS in LABC in a large nationwide oncology database.MethodsWe identified ≥ pT3pN0‐3M0 LABC patients in the National Cancer Database diagnosed 2004‐2014 who underwent RC ± PORT. OS was calculated using Kaplan‐Meier and Cox proportional hazards regression modeling was used to identify predictors of OS. Propensity matching was performed to match RC patients who received PORT vs those who did not.Results15,124 RC patients were identified with 512 (3.3%) receiving PORT. Median OS was 20.0 months (95% CI, 18.2‐21.8) for PORT vs 20.8 months (95% CI, 20.3‐21.3) for no PORT (P = 0.178). In multivariable analysis, PORT was independently associated with improved OS: hazard ratio 0.87 (95% CI, 0.78‐0.97); P = 0.008. A one‐to‐three propensity match yielded 1,858 patients (24.9% receiving PORT and 75.1% without). In the propensity‐matched cohort, median OS was 19.8 months (95% CI, 18.0‐21.6) for PORT vs 16.9 months (95% CI, 15.6‐18.1) for no PORT (P = 0.030). In the propensity‐matched cohort of urothelial carcinoma patients (N = 1,460), PORT was associated with improved OS for pT4, pN+, and positive margins (P < 0.01 all).ConclusionIn this observational cohort, PORT was associated with improved OS in LABC. While the data should be interpreted cautiously, these results lend support to the use of PORT in selected patients with LABC, regardless of histology. Prospective trials of PORT are warranted.
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, James L. , Antonarakis, Emmanuel S. , Armstrong, Andrew J. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, James A., Enke, Charles A. , Farrington, Thomas A., Higano, Celestia S. , Horwitz, Eric M. , Kuettel, Michael, McKenney, Jesse K. , Netto, George J. , Penson, David F. , Pow‐Sang, Julio M. , Pugh, Thomas J., Richey, Sylvia, Roach, Mack , Rosenfeld, Stan, Schaeffer, Edward M. , Shabsigh, Ahmad , Spratt, Daniel E. , Srinivas, Sandy, Tward, Jonathan D. , Shead, Dorothy A. , Freedman-Cass, Deborah A., Antonarakis, Emmanuel S. , Davis, Brian J. , Spratt, Daniel E , Antonarakis, Emmanuel S , Armstrong, Andrew J , Antonarakis, Emmanuel S , Hurwitz, Michael E. , Ippolito, Joseph E. , Kane, Christopher J. , Lang, Joshua M. , Plimack, Elizabeth R. , Small, Eric J.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 22, 2019 | Volume: 17 | Issue: 5 | Pages: 479-505

10.6004/jnccn.2019.0023 | PMID 31085757 Get It

The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer. The portions of the guidelines included herein focus on the roles of germline and somatic genetic testing, risk stratification with nomograms and tumor multigene molecular testing, androgen deprivation therapy, secondary hormonal therapy, chemotherapy, and immunotherapy in patients with prostate cancer.
Radial artery access is under‐utilized in women undergoing PCI despite potential benefits: Mayo Clinic PCI Registry
Chester, Rebecca , Mina, Syeda A. , Lewis, Bradley R., Butterfield, Richard , Chester, Rebecca C , Zhang, Nan , Yang, Eric H.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 22, 2019 | Volume: 95 | Issue: 4 | Pages: 675-683

10.1002/ccd.28341 | PMID 31115141 Get It

Abstract Background Women may benefit from radial artery access (RAA) for percutaneous coronary interventions (PCI) due to a higher risk of bleeding compared to men; however, RAA may be underutilized in women. We sought to determine the frequency and predictors of RAA use in patients undergoing PCI. Methods We studied 21,123 (29.0% female) participants in the Mayo Clinic PCI Registry from January 1, 2006–December 31, 2016. Data were analyzed as a cohort and by time tertiles. Frequency of RAA versus femoral access and bleeding events were recorded. Logistic regression was used to identify predictors of RAA. Results In the overall cohort, women compared to men were older (69.6 ± 12.6 vs. 65.6 ± 11.9; p < .001), more likely to present with acute coronary syndrome (82.0% in women vs. 80.0% in men; p = .0008) and had more comorbidities. RAA increased from tertile one (3.5% for women vs. 4.0% for men; p = .3) through tertile three (46.8% for women vs. 50.3% for men; p = .01), but remained lower in women. In multivariable analysis, female sex is associated with 22% less RAA use (OR 0.78, 95% CI 0.72–0.84; p < .0001). Women compared to men experienced more bleeding (6.3 vs. 3.0%; p < .0001) but bleeding was less likely in RAA (OR 0.45, 95% CI 0.36–0.56; p < .0001). Conclusion Women undergoing PCI are less likely to receive RAA compared to men despite having a higher risk of bleeding. This trend persists despite increase in RAA use. Given the potential benefit of RAA in women, sex should be considered in patient selection for RAA.
Essential Office Procedures for Medicare Patients in Primary Care: Comparison With Family Medicine Residency Training
Poulin, Eric A., Swartz, Andrew W. , O'Grady, J. , Kersten, Mclean Phillip M., Angstman, Kurt B. , O'Grady, Jason S, O'Grady, Jason S

Mayo Clinic

Family Medicine | May 21, 2019 | Volume: 51 | Issue: 7 | Pages: 574-577

10.22454/fammed.2019.659478 | PMID 31125421 Get It

Background and Objectives: Demographic trends show an increasing older adult population. Therefore, family medicine training programs may need to reevaluate how well their residents perform clinic procedures essential to older adults. Our objective was to compare the rates of the most frequently performed clinic procedures for Medicare patients in a large multiregional health care system (MRHCS) with those in a family medicine residency clinic. Methods: In this retrospective cohort study, Current Procedural Terminology coding data were queried from the billing systems of an MRHCS (the control group) and a family medicine residency clinic (the study group) for a 3-year period. The primary outcome was the procedural rate ratios per 1,000 office visits for the 10 most common clinic procedures in the MRHCS billed to Medicare. Results: The study group consisted of 19,099 office visits by Medicare patients to the residency clinic; the control group consisted of 2,034,188 visits to the MRHCS. Except for large joint injection, procedural rates were significantly different for the other nine procedures (destruction of benign skin lesions, nail care, punch or shave skin biopsy, removal of impacted cerumen, wound debridement of skin, Unna boot application, excision of skin lesion, paring of corn or callus, and insertion of bladder catheter). The rate of skin excision was higher in the residency clinic than in the MRHCS but lower for the other eight procedures. Conclusions: These data suggest that teaching programs may need to adapt to meet the current and future practice needs of this increasing patient population.
Does Neck Disability Index Correlate With 12-Month Satisfaction After Elective Surgery for Cervical Radiculopathy? Results From a National Spine Registry
Khan, Inamullah , Sivaganesan, Ahilan, Archer, Kristin R. , Bydon, Mohamad , McGirt, Matthew J., Nian, Hui , Foley, Kevin T. , Mummaneni, Praveen V. , Bisson, Erica F. , Shaffrey, Christopher I. , Asher, Anthony L. , Devin, Clinton J. , Sites, QOD Vanguard, Sorenson, Jeffrey, Briggs, Thomas B., Kremer, Adam, Griffitt, Wesley E., Shaffrey, Mark E., Fassett, Daniel R. , Oetting, Gregory, Elowitz, Eric , Rumana, Christopher S., Harrell, Frank E. , Harbaugh, Robert E. , Sites, QOD Vanguard

Mayo Clinic

Neurosurgery | May 16, 2019 | Volume: 86 | Issue: 5 | Pages: 736-741

10.1093/neuros/nyz231 | PMID 31268151 Get It

Abstract BACKGROUND Modern healthcare reforms focus on identifying and measuring the quality and value of care. Patient satisfaction is particularly important in the management of degenerative cervical radiculopathy (DCR) since it leads to significant neck pain and disability primarily affecting the patients’ quality of life. OBJECTIVE To determine the association of baseline and 12-mo Neck Disability Index (NDI) with patient satisfaction after elective surgery for DCR. METHODS The Quality Outcomes Database cervical module was queried for patients who underwent elective surgery for DCR. A multivariable proportional odds regression model was fitted with 12-mo satisfaction as the outcome. The covariates for this model included patients’ demographics, surgical characteristics, and baseline and 12-mo patient reported outcomes (PROs). Wald-statistics were calculated to determine the relative importance of each independent variable for 12-mo patient satisfaction. RESULTS The analysis included 2206 patients who underwent elective surgery for DCR. In multivariable analysis, after adjusting for baseline and surgery specific variables, the 12-mo NDI score showed the highest association with 12-mo satisfaction (Waldχ2-df = 99.17, 58.1% of total χ2). The level of satisfaction increases with decrease in 12-mo NDI score regardless of the baseline NDI score. CONCLUSION Our study identifies 12-mo NDI score as a very influential driver of 12-mo patient satisfaction after surgery for DCR. In addition, there are lesser contributions from other 12-mo PROs, baseline Numeric Rating Scale for arm pain and American Society of Anesthesiologists (ASA) grade. The baseline level of disability was found to be irrelevant to patients. They seemed to only value their current level of disability, compared to baseline, in rating satisfaction with surgical outcome.
Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score
Holmes, DaJuanicia N. , Piccini, Jonathan P. , Kowey, Peter R. , O’Brien, Emily C. , Reiffel, James A. , Ezekowitz, Michael D. , Singer, Daniel E. , Spertus, John A. , Thomas, Laine , Patients, on behalf of the ORBIT-AF Investigators and, Spertus, John A , Allen, Larry A. , Fonarow, Gregg C. , Gersh, Bernard J. , Naccarelli, Gerald V. , Chan, Paul S. , Peterson, Eric D. , Patients, on behalf of the ORBIT-AF Investigators and

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | May 16, 2019 | Volume: 12 | Issue: 5 | Pages: No page available

10.1161/circoutcomes.118.005358 | PMID 31092022 Get It

Background: The Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire has recently been validated to measure the impact of atrial fibrillation on quality of life, but a clinically important difference in AFEQT score has not been well defined. Methods and Results: To determine the clinically important difference in overall AFEQT (score range= 0 [worst] to 100 [best]) and selected subscales, we analyzed data in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry, a United States-based outpatient atrial fibrillation registry. AFEQT was assessed at baseline and 1 year in a subset of 1347 ORBIT-AF patients from 80 US sites participating in ORBIT-AF from June 2010 to August 2011. The mean change method was used to relate changes in 1-year AFEQT scores to clinically important changes in the physician assessment of European Heart Rhythm Association functional status (1 class improvement and separately 1 class deterioration). Clinically important differences and 95% CI corresponding to either a 1 European Heart Rhythm Association class improvement or deterioration were 5.4 (3.6–7.2) and −4.2 (−6.9 to −1.5) AFEQT points, respectively. Similarly, clinically important difference values were seen for a 1 European Heart Rhythm Association class improvement for the AFEQT subscales Activities of Daily Living and Symptoms: 5.1 (2.5–7.6) and 7.1 (5.3–9.0) AFEQT points, respectively. Conclusions: Based on the anchor of 1 European Heart Rhythm Association class change, changes in AFEQT score of + or −5 points are clinically important changes in patients’ health. Clinical Trial Registration: URL: https://clinicaltrials.gov . Unique identifier: NCT01165710.
β2‐Adrenergic Receptor Gene Affects the Heart Rate Response of β‐Blockers: Evidence From 3 Clinical Studies
Shahin, Mohamed H. , Rouby, Nihal El , Conrado, Daniela J., González, Daniel , Lobmeyer, Maximilian T. , Beitelshees, Amber L. , Boerwinkle, Eric , Gums, John G. , Chapman, Arlene B. , Pepine, Carl J. , Johnson, Julie A. , Beitelshees, Amber L. , Turner, Stephen T. , Gong, Yan , Chapman, Arlene B. , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

The Journal of Clinical Pharmacology | May 15, 2019 | Volume: 59 | Issue: 11 | Pages: 1462-1470

10.1002/jcph.1443 | PMID 31090079 Get It

Abstractβ‐Blockers’ heart rate (HR)‐lowering effect is an important determinant of the effectiveness for this class of drugs, yet it is variable among β‐blocker–treated patients. To date, genetic studies have revealed several genetic signals associated with HR response to β‐blockers. However, these genetic signals have not been consistently replicated across multiple independent cohorts. Here we sought to use data from 3 hypertension clinical trials to validate single‐nucleotide polymorphisms (SNPs) previously associated with the HR response to β‐blockers. Using linear regression analysis, we investigated the effects of 6 SNPs in 3 genes, including ADRB1, ADRB2, and GNB3, relative to the HR response following β‐blocker used in the PEAR (n = 757), PEAR‐2 (n = 368), and INVEST (n = 1401) trials, adjusting for baseline HR, age, sex, and ancestry. Atenolol was used in PEAR and INVEST, and metoprolol was used in PEAR‐2. We found that rs1042714 and rs1042713 in ADRB2 were significantly associated with HR response to both β‐blockers in whites (rs1042714 C‐allele carriers, meta‐analysis β = –0.95 beats per minute [bpm], meta‐analysis P = 3×10–4; rs1042713 A‐allele carriers, meta‐analysis β = –1.15 bpm, meta‐analysis P = 2×10–3). In conclusion, the results of our analyses provide strong evidence to support the hypothesis that rs1042714 and rs1042713 in the ADRB2 gene are important predictors of HR response to cardioselective β‐blockade in hypertensive patient cohorts.
Update on the Prenatal Diagnosis and Outcomes of Fetal Bilateral Renal Agenesis
Huber, Carola , Blumenfeld, Yair J. , Jelin, Eric B. , Shazly, Sherif A. , Ruano, Rodrigo

Mayo Clinic

Obstetrical & Gynecological Survey | May 13, 2019 | Volume: 74 | Issue: 5 | Pages: 298-302

10.1097/ogx.0000000000000670 | PMID 31098643 Get It

Importance Bilateral renal agenesis is a rare congenital anomaly associated with poor prognosis. Objective The aims of this article are to review and summarize evidence on prenatal diagnosis and outcomes of bilateral renal agenesis. Evidence Acquisition A search was undertaken using PubMed and ClinicalTrials.gov databases from January 1, 1998, to September 1, 2018. Search terms include “prenatal diagnosis” OR “outcomes” AND “bilateral renal agenesis.” Search was limited to English language. Results Fetal ultrasonography is the primary imaging modality for prenatal diagnosis of fetal urogenital tract abnormalities. However, ultrasonography is limited by several factors; it is operator dependent and associated with small field of view, has limited soft-tissue acoustic contrast, and is also influenced by patient habitus and fetal position. Color Doppler ultrasonography can be used as an adjunct to exclude bilateral renal agenesis by visualizing renal arteries. In the literature, prenatal magnetic resonance imaging has been reported to be equal to or superior to prenatal ultrasonography. Bilateral renal agenesis with oligohydramnios/anhydramnios is associated with a poor prognosis; perinatal death occurs secondary to pulmonary hypoplasia in the majority of cases. Conclusions Ultrasonography in combination with color Doppler ultrasonography permits the fetal urinary tract to be assessed in the first and early second trimester of gestation. The magnetic resonance imaging can be used as a complementary adjunctive modality in equivocal or inconclusive ultrasonographic findings. Target Audience Obstetricians and gynecologists, family physicians. Learning Objectives After completing this activity, the learner should be able to describe the natural history of fetuses with bilateral renal agenesis; explain to patients the accuracy and limitations of the prenatal diagnosis of the anomaly; and counsel patients regarding the perinatal outcome and prognosis of fetuses with this condition.
Endoscopic Bariatric Therapy: A Guide to the Intragastric Balloon
Bazerbachi, Fateh , Vargas, Eric J. , Dayyeh, Barham K. Abu , Abu Dayyeh, Barham K

Mayo Clinic

American Journal of Gastroenterology | May 13, 2019 | Volume: 114 | Issue: 9 | Pages: 1421-1431

10.14309/ajg.0000000000000239 | PMID 31082868 Get It

Intragastric balloons (IGBs) are the most widely available endoscopic bariatric therapy for class I and II obesity in the United States. Although simple in application and reversible by nature, these devices may help patients initiate the important first steps in weight loss maintenance, provided that parallel efforts are in motion to prevent weight recidivism. Too often, therapeutic nihilism stems from unrealistic expectations of a given therapy. In the case of IGBs, this sentiment may occur when these interventions are applied in a vacuum and not within the purview of a multidisciplinary program that actively involves dieticians, endocrinologists, gastroenterologists, and surgeons. There is a clear and present need to apply different tactics in the remissive strategy to control the obesity pandemic, more so in a struggling landscape of an ever-widening gap in bridging interventions. With such demand, the IGB is an available tool that could be helpful when correctly implemented. In this exposition, we summarize the current state of IGBs available worldwide, discuss their mechanism of action, relay evidence for their short- and long-term efficacy, address safety profile concerns, and suggest procedural considerations in the real-world quotidian application.